Herbs (Global Traditional) · European
Peppermint (Mentha piperita) (Mentha piperita)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Peppermint (Mentha piperita) contains menthol, which activates TRPM8 channels and blocks calcium channels to provide antispasmodic effects. Clinical evidence supports its use for irritable bowel syndrome symptoms and menstrual pain relief.
Peppermint (Mentha × piperita) is a hybrid mint plant derived from a cross between spearmint and watermint, native to Europe and the Mediterranean region. The aerial parts (leaves and stems) are harvested and typically dried or processed into essential oil through steam distillation, yielding a volatile oil rich in menthol and menthone.
A meta-analysis of 12 randomized controlled trials (n=835 patients) demonstrated peppermint oil's efficacy for IBS with a number needed to treat of 3 for global symptoms. However, recent large RCTs including a 6-week trial (n=190) and an 8-week Dutch trial (n=189) failed to meet primary endpoints for abdominal pain response. A systematic review of 5 RCTs (n=499) supported peppermint's use for menstrual disorders.
Enteric-coated peppermint oil capsules: 180-182 mg three times daily for 6-8 weeks (IBS). Colpermin formulation: One capsule 3-4 times daily, 15-30 minutes before meals. For hypertension (under investigation): 100 μL daily. Most clinical trials use enteric-coated formulations to enable targeted intestinal release. Consult a healthcare provider before starting any new supplement.
Fresh peppermint leaves (per 100 g): Energy ~70 kcal; Protein ~3.8 g; Total fat ~0.9 g; Carbohydrates ~14.9 g; Dietary fiber ~8.0 g; Water ~78 g. Key micronutrients: Iron ~5.1 mg (28% DV, non-heme form with lower bioavailability ~2–10%, enhanced by co-consumption with vitamin C), Manganese ~1.2 mg (52% DV), Copper ~0.33 mg (37% DV), Magnesium ~80 mg (19% DV), Calcium ~243 mg (24% DV, moderate bioavailability due to oxalate content), Potassium ~569 mg (12% DV), Folate ~114 µg (29% DV), Vitamin A (as carotenoids) ~4248 IU (85% DV, bioavailability improved with dietary fat), Vitamin C ~31.8 mg (35% DV), Riboflavin ~0.26 mg (20% DV). Primary bioactive compounds: Essential oil (1.2–3.9% of dry weight) dominated by menthol (30–55% of oil), menthone (14–32%), menthyl acetate (2.8–10%), 1,8-cineole (3.5–14%), and menthofuran (1–9%). Rosmarinic acid is the major phenolic compound (~12–75 mg/g dry extract depending on preparation), with demonstrated antioxidant and anti-inflammatory properties; bioavailability of rosmarinic acid is moderate (peak plasma at ~0.5–1 hr, partially metabolized to caffeic acid and ferulic acid). Additional polyphenols include eriocitrin (~2–12 mg/g dry extract), luteolin-7-O-rutinoside, and hesperidin. Triterpenes include ursolic acid and oleanolic acid (~0.5–1.5% dry weight). Typical therapeutic doses use enteric-coated peppermint oil capsules delivering 0.2–0.4 mL oil per dose (approximately 90–180 mg menthol per capsule); enteric coating is critical for IBS applications to prevent premature gastric release and esophageal reflux. Peppermint tea (1.5–2 g dried leaf per 150 mL, steeped 5–10 min) delivers substantially less essential oil (~0.02–0.04 mL) but meaningful amounts of rosmarinic acid and flavonoids. Note: Culinary/tea quantities of fresh or dried leaf contribute negligible calories but meaningful micronutrient top-ups; the concentrated essential oil form is the primary vehicle for therapeutic bioactive delivery.
Menthol, peppermint's primary bioactive compound, activates TRPM8 (cold-sensitive) channels and blocks voltage-gated calcium channels in smooth muscle cells. This dual action reduces muscle contractility and provides antispasmodic effects in the gastrointestinal tract. Menthol also modulates pain perception through TRPA1 channel interactions and local anesthetic properties.
A meta-analysis of 12 randomized controlled trials (n=835) demonstrated significant improvements in IBS global symptoms (RR 2.39) and abdominal pain (RR 1.78), though recent larger trials show inconsistent results. For menstrual pain, a systematic review of 5 RCTs (n=499) found significant pain reductions compared to placebo. Most studies used enteric-coated peppermint oil capsules containing 0.2-0.4ml per dose. The evidence quality is moderate, with some studies showing methodological limitations.
Peppermint oil is generally well-tolerated but can cause heartburn, nausea, and perianal burning in some individuals. It may enhance the absorption of certain medications due to its permeability-enhancing effects on intestinal membranes. Peppermint can potentially interact with calcium channel blockers and may worsen gastroesophageal reflux disease. Pregnancy and breastfeeding safety data is limited, so use should be avoided during these periods without medical supervision.
